Core Viewpoint - The controlling shareholder, Jiangsu Hengshun Group Co., Ltd., has initiated a share buyback of Hengshun Vinegar through the Shanghai Stock Exchange, indicating confidence in the company's future performance and potential growth [1] Summary by Relevant Sections Share Buyback Details - Jiangsu Hengshun Group has purchased 1.4225 million A-shares, representing 0.13% of the total share capital, with a transaction amount of 11.2291 million yuan [1] - The total shares acquired so far amount to 1.4225 million, with a cumulative investment of 11.2291 million yuan, also constituting 0.13% of the total share capital [1] Future Buyback Plans - The group plans to continue increasing its stake in Hengshun Vinegar from May 24, 2025, to May 23, 2026, with an investment range of 50 million to 100 million yuan [1] - The intended increase in shareholding will not exceed 2% of the company's total share capital [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 上市公司的名称：华熙生物科技股份有限公司 股票上市地点：上海证券交易所 股票简称：华熙生物 股票代码：688363 信息披露义务人： 名称：华熙昕宇投资有限公司 住所：北京市密云区冯家峪镇政府南文化中心院内115室 通讯地址：北京市朝阳区建国门外大街甲6号华熙国际中心D座35层 信息披露义务人之一致行动人： 姓名：赵燕 通讯地址：北京市朝阳区建国门外大街甲6号华熙国际中心D座33层 信息披露义务人之一致行动人： 名称：上海琰泽企业管理合伙企业（有限合伙） 一、本报告系信息披露义务人依据《中华人民共和国证券法》、《上市公司收购管理办法》、《公开发 行证券的公司信息披露内容与格式准则第15号——权益变动报告书》及相关的法律和法规编写。 二、信息披露义务人签署本报告书已获得必要的授权和批准。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本报告书已全面披露了信息 披露义务人在华熙生物科技股份有限公司中拥有权益的股份变动情况。 截至本报告书签署之日，除本报告书披露的信息外，信息披露义务人没有通过任何其他方式增加或减少 其在华熙生物科技股份有限公司中 ...

Core Viewpoint - Huazhou City A (华侨城Ａ) experienced a limit-up on September 22, 2025, with a price of 2.75 yuan, reflecting a 9.2% increase, and a total market capitalization of 21.943 billion yuan [1] Group 1: Governance and Management Changes - The company has been actively reforming its governance structure, including revising shareholder meeting rules and improving the independent director system, which enhances governance transparency and standardization, benefiting long-term development [2] - The controlling shareholder plans to increase its stake by 111 to 220 million yuan, demonstrating confidence in the company [2] - A new chairman and acting president, Wu Bingqi, has been appointed, which may bring new strategic directions and positive market expectations [2] Group 2: Financial Performance - The company's operating cash flow turned positive in the first half of 2025, showing significant year-on-year improvement [2] - The average financing cost decreased to 3.5%, down 11 basis points from the beginning of the year [2] - The cultural tourism business remains resilient through the introduction of special activities, indicating long-term growth potential despite short-term weather impacts [2] Group 3: Market Dynamics - On September 22, stocks in the real estate and cultural tourism sectors saw a simultaneous rise, indicating a sector-wide correlation effect [2] - Technical indicators such as MACD and BOLL channel signals are being monitored for potential bullish trends, which could further support stock price increases [2]

Group 1 - The core point of the announcement is that Guangxi Wuzhou Transportation Co., Ltd. received a loan commitment letter from CITIC Bank to support the shareholding increase plan of its controlling shareholder, Guangxi Transportation Investment Group Co., Ltd. The maximum loan amount is RMB 153 million [1][2]. - The shareholding increase plan involves Guangxi Transportation Investment Group intending to increase its stake in the company within 12 months starting from September 15, 2025, with a planned investment amount between RMB 85 million and RMB 170 million [1][2]. - The loan from CITIC Bank is subject to meeting specific loan conditions and regulatory requirements, with the loan term not exceeding three years and the funds exclusively for increasing company shares [2][3].

Core Viewpoint - The controlling shareholder of Anhui Construction Group Co., Ltd. has successfully completed a share buyback plan, demonstrating confidence in the company's future development and long-term investment value [2][3][6]. Summary by Sections Share Buyback Plan - The controlling shareholder, Anhui Construction Group Holdings Co., Ltd., announced a plan to increase its stake in the company by acquiring between 1% and 2% of the total shares, with a maximum investment of RMB 200 million [2]. - The buyback plan was executed from May 29 to September 12, 2025, resulting in the acquisition of 34,330,010 A-shares, which is approximately 2.00% of the total share capital, amounting to RMB 163,076,974.28 (excluding taxes) [2][3]. Shareholding Changes - As of September 12, 2025, the controlling shareholder held a total of 585,968,794 shares, representing 34.14% of the company's total share capital [6]. - The buyback activity was conducted in compliance with relevant laws and regulations, and it did not affect the company's listing status or change the controlling shareholder [6]. Legal Compliance and Disclosure - The company has fulfilled its information disclosure obligations in accordance with the Shanghai Stock Exchange's rules and regulations [6]. - A legal opinion was provided by Anhui Tianhe Law Firm regarding the buyback, confirming its compliance with applicable laws [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002252 证券简称：上海莱士 公告编号：2025-063 上海莱士血液制品股份有限公司 关于控股股东增持公司股份计划实施完成的公告 公司控股股东海盈康（青岛）医疗科技有限公司保证向本公司提供的信息内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 特别提示： 1、增持计划的主要内容：上海莱士血液制品股份有限公司（"上海莱士"、"公司"）于2025年5月22日披 露了《关于控股股东增持股份计划的公告》（公告编号：2025-043），基于对上海莱士未来发展的信心 和长期投资价值的认同，增强投资者信心，控股股东海盈康（青岛）医疗科技有限公司（"海盈康"）计 划自本次增持计划公告披露之日起6个月内（除法律、法规及深圳证券交易所业务规则等有关规定不准 增持公司股票的期间之外），通过集中竞价方式增持公司股份，拟增持金额不低于人民币25,000万元， 且不超过人民币50,000万元（均含本数且不包含交易费用）（以下简称"本次增持计划"）。本次增持计 划不设置增持价格区间，增持主体基于 ...

Core Viewpoint - The controlling shareholder of Shanghai Pharmaceuticals, Shanghai Shiyuan Group, plans to increase its stake in the company through its wholly-owned subsidiary, Shanghai Shiyuan International Investment Co., Ltd. [2][3] Group 1: Basic Information of the Increasing Entity - The increasing entity, Shanghai Shiyuan International Investment Co., Ltd., is a wholly-owned subsidiary of Shanghai Shiyuan Group, which is the controlling shareholder of Shanghai Pharmaceuticals [2]. - After the recent purchase of 100,000 H-shares on September 15, 2025, Shanghai Shiyuan International now holds 300,538,000 H-shares, accounting for 8.104% of the total share capital of the company [2]. Group 2: Main Content of the Increasing Plan - The controlling shareholder, Shanghai Shiyuan Group, plans to increase its stake through Shanghai Shiyuan International by acquiring between 55 million to 74 million H-shares over the next 12 months, not exceeding 2% of the company's voting shares [3]. - The increase will be executed through the Hong Kong Stock Exchange's centralized bidding system, with no fixed price range set for the purchases, allowing for flexibility based on market conditions [3]. Group 3: Other Relevant Information - The increasing plan complies with the relevant laws and regulations, including the Securities Law of the People's Republic of China and the Hong Kong Securities and Futures Commission's rules [7]. - The controlling shareholder and its subsidiaries commit not to reduce their holdings of the company's shares during the implementation of the increasing plan and for six months thereafter [7].

Core Viewpoint - The company, Meizhong Jiahua (02453), announced that its controlling shareholder, Concord Medical Services Holdings Limited (CCM), plans to increase its stake in the company within the next 12 months [1] Group 1: Shareholder Actions - CCM intends to acquire shares through its subsidiaries using its own funds in the open market [1] - The specific details of the share acquisition will be disclosed in accordance with regulations [1] Group 2: Strategic Intent - The share buyback plan aims to solidify CCM's controlling position and increase its ownership percentage [1] - This move is intended to convey a positive message to the market regarding CCM's confidence in the company's future prospects and long-term development [1]

Core Viewpoint - Concord Medical Services Holdings Limited (CCM) plans to increase its stake in the company within 12 months, signaling confidence in the company's future prospects [1] Group 1 - CCM will conduct the share buyback through its subsidiaries using its own funds in the open market [1] - The buyback aims to consolidate CCM's controlling position and increase its shareholding percentage [1] - The company will disclose specific buyback transactions in accordance with regulations [1]

增持计划旨在巩固CCM的控股地位，提高CCM的持股比例，并向市场传递控股股东对集团未来前景及 长远发展充满信心的积极信息。 格隆汇9月12日丨美中嘉和(02453.HK)发布公告，公司获公司控股股东Concord Medical Services Holdings Limited("CCM")告知，CCM计划于本公告起计12个月内增持公司股权。公司已获告知，为进行增持， CCM将透过其附属公司以自有资金于公开市场进行增持，具体增持交易将根据规则及时披露。 ...